Nabriva Therapeutics plc
NBRVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $35,668 | $27,216 | $5,027 | $7,748 |
| % Growth | 31.1% | 441.4% | -35.1% | – |
| Cost of Goods Sold | $28,581 | $13,148 | $1,586 | $70 |
| Gross Profit | $7,087 | $14,068 | $3,441 | $7,678 |
| % Margin | 19.9% | 51.7% | 68.5% | 99.1% |
| R&D Expenses | $14,263 | $12,630 | $15,102 | $26,415 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $45,264 | $51,645 | $55,285 | $62,485 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,050 | -$1,679 | -$820 | -$1,733 |
| Operating Expenses | $62,577 | $62,596 | $69,567 | $87,167 |
| Operating Income | -$55,490 | -$48,528 | -$66,126 | -$79,489 |
| % Margin | -155.6% | -178.3% | -1,315.4% | -1,025.9% |
| Other Income/Exp. Net | -$127 | -$432 | -$3,219 | -$3,174 |
| Pre-Tax Income | -$55,617 | -$48,960 | -$69,345 | -$82,663 |
| Tax Expense | $1,568 | $490 | $139 | $101 |
| Net Income | -$57,185 | -$49,450 | -$69,484 | -$82,764 |
| % Margin | -160.3% | -181.7% | -1,382.2% | -1,068.2% |
| EPS | -21.32 | -28.52 | -135.23 | -278.75 |
| % Growth | 25.2% | 78.9% | 51.5% | – |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.75 |
| Weighted Avg Shares Out | 2,682 | 1,734 | 514 | 297 |
| Weighted Avg Shares Out Dil | 2,682 | 1,734 | 514 | 297 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $86 | $255 |
| Interest Expense | $698 | $901 | $1,735 | $3,644 |
| Depreciation & Amortization | $217 | $637 | $820 | $770 |
| EBITDA | -$54,702 | -$47,422 | -$66,876 | -$78,719 |
| % Margin | -153.4% | -174.2% | -1,330.3% | -1,016% |